S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
Log in

TSE:GENGeneNews Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume473,148 shs
Average Volume1.48 million shs
Market CapitalizationC$24.65 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-905-7392030

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$234,592.00
Book ValueC($0.06) per share

Profitability

Miscellaneous

Employees15
Market CapC$24.65 million
Next Earnings DateN/A
OptionableOptionable
30 days | 90 days | 365 days | Advanced Chart

Receive GEN News and Ratings via Email

Sign-up to receive the latest news and ratings for GEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











GeneNews (TSE:GEN) Frequently Asked Questions

Has GeneNews been receiving favorable news coverage?

News coverage about GEN stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. GeneNews earned a news impact score of 1.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term.
View the latest news about GeneNews
.

Who are some of GeneNews' key competitors?

What other stocks do shareholders of GeneNews own?

Who are GeneNews' key executives?

GeneNews' management team includes the following people:
  • Mr. James R. Howard-Tripp, Exec. Chairman & CEO
  • Ms. Joanna M. Halsey Esq., Gen. Counsel, Chief Compliance Officer & HR Director of IDL
  • Prof. Choong-Chin Liew Ph.D., Co-Founder
  • Mr. Warren Whitehead, Chief Accountant (Age 67)
  • Mr. David Suria, Sr. Scientist

What is GeneNews' stock symbol?

GeneNews trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GEN."

How do I buy shares of GeneNews?

Shares of GEN and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

How big of a company is GeneNews?

GeneNews has a market capitalization of C$24.65 million and generates C$234,592.00 in revenue each year. GeneNews employs 15 workers across the globe.

What is GeneNews' official website?

The official website for GeneNews is www.genenews.com.

How can I contact GeneNews?

GeneNews' mailing address is 445 Apple Creek Blvd Unit 220, MARKHAM, ON L3R 9X7, Canada. The company can be reached via phone at +1-905-7392030.

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.